-
Current FDA Safety Investigation: NAION With Mounjaro, Zepbound, and Other GLP-1 RAs
Evaluating Glucagon-like Peptide-1 (GLP-1) Receptor Agonists for Possible Risk of NAION Side Effects (Posted by Tom Lamb at Drug Injury Watch) The FDA has been investigating "potential signals" of non-arteritic anterior ischemic optic neuropathy (NAION)…
-
Ozempic Vision Loss Lawsuits Have Been Filed by Patients Against Novo Nordisk
We List Some of the Legal Liability Allegations Regarding Drug Company Actions and Failures (Posted by Tom Lamb at Drug Injury Watch) During the past several weeks, Ozempic vision loss lawsuits have been filed by…
-
March 2025 Medical Article About Blindness or Vision Loss Linked to Ozempic and Rybelsus Use by Diabetes Patients
Discusses Timing for Increased Risk of Semaglutide-related Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Side Effect (Posted by Tom Lamb at Drug Injury Watch) On March 27, 2025, the JAMA Ophthalmology medical journal published a report…
-
Ozempic Vision Problems From Semaglutide Apply to Wegovy and Rybelsus, Also
NAION Eye Side Effect Risk Increased With Semaglutide Drugs – Two Recent Medical Studies (Posted by Tom Lamb at Drug Injury Watch) UPDATE: The [European Medicines Agency (EMA)] Pharmacovigilance Risk Assessment Committee (PRAC) reviewed all available…
-
Meningioma Warning For Depo-Provera Recommended in Europe by Drug Regulator
Why Has This September 2024 European Medicines Agency (EMA) Action Not Been Followed by FDA in US? (Posted by Tom Lamb at Drug Injury Watch) One of the primary issues in the increasing number of…
